Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Raman Spectroscopy, Children, Only
Interventions: Feeding trial; Other
Lead sponsor: Utah State University; Other
Eligibility: 5 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Obesity
Interventions: mental contrasting with implementation intentions, telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!, Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All, Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Wound
Interventions: Standard of Care Treatment or Standard of Care Treatment plus Miro3D Wound Matrix; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ankle Sprains, Ankle Injuries and Disorders
Interventions: Walking, Rucking, Running; Other
Lead sponsor: Danielle Torp; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Lexington, Kentucky • Charlotte, North Carolina

Conditions: Healthy Volunteers
Interventions: TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions: Radiation Therapy, Temozolomide, Bevacizumab; Radiation · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Participants
Interventions: S-740792 Suspension, Midazolam, Placebo, S-740792 Tablet; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Dental Caries
Interventions: C16G2; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Conditions: Hepatitis C
Interventions: Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: No intervention; Other
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Ann Arbor, Michigan + 6 more

Conditions: Lung; Node, Adenocarcinoma of Lung
Interventions: DetermaRX; Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Opioid-use Disorder
Interventions: PROUD Intervention; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 16 Years to 90 Years
Enrollment: 377,373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Detroit, Michigan • The Bronx, New York + 3 more

Conditions: Adolescent Development
Interventions: Skeletal loading; Other
Lead sponsor: University of Arizona; Other
Eligibility: 9 Years to 12 Years · Female only
Enrollment: 509 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Primary Sclerosing Cholangitis
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 34
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Non-small Cell Lung Cancer(NSCLC)
Interventions: AT13387, Crizotinib; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 38
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 31 more

Conditions: Acute Ischemic Stroke
Interventions: Endovascular Thrombectomy, Medical Management; Device · Other
Lead sponsor: Amrou Sarraj; Other
Eligibility: 18 Years to 85 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Kansas City, Kansas • St Louis, Missouri + 3 more

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 16 more

Conditions: Hepatocellular Carcinoma
Interventions: Tremelimumab, Durvalumab, Bevacizumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 16
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more

Conditions: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Interventions: Pocenbrodib, Pocenbrodib and Darolutamide; Drug
Lead sponsor: Pathos AI, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
Interventions: Venetoclax, Fludarabine, Busulfan, Azacitidine, Decitabine/cedazuridine; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anemia, Sickle Cell
Interventions: Mindfulness-based Stress Reduction; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 106
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: NLY01; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

The Effect of a Nutrient Dense Food on the Skin CarotenoidLevels of School Age Children

WOOP VA: Promoting Weight Management in Primary Care

Miro3D Randomized Controlled Trial (RCT)

Auditory Biofeedback Gait Training Individuals With Chronic Ankle Instability

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Bevacizumab Beyond Progression (BBP)

A Study of S-740792 in Healthy Adult Study Participants

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

Drug Interaction & Methadone & Buprenorphine

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

PRimary Care Opioid Use Disorders Treatment (PROUD) Trial

Jump-In: Building Better Bones

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

MBSR for Pain Catastrophizing in SCD

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects